Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AM3 + SynBalance Metsyn
- Development stage
- Unknown
- Lead developer
- SynBalance
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
AM3 + SynBalance Metsyn is a **combination nutritional supplement** consisting of the immunomodulator **AM3** and the probiotic complex **SynBalance Metsyn**. AM3 is known for its anti-inflammatory and immune-regulatory properties, while SynBalance Metsyn is a blend of multispecies probiotics (*Lactobacillus plantarum PBS067*, *Lactobacillus reuteri PBS072*, *Lactobacillus acidophilus PBS066*) designed to support **metabolic syndrome** through modulation of lipid metabolism, carbohydrate absorption, reduction of systemic and intestinal inflammation, and enhancement of antioxidant defenses. Clinical trials and preclinical studies have shown improvements in metabolic and inflammatory markers, lipid profiles, glycemic control, and a reduction in chronic pathology in subjects with metabolic syndrome. The combination targets inflammatory and metabolic mediators, aiming to minimize risk factors associated with metabolic syndrome and support vascular health[1][2][3][5].
- Other names
- SynBÆctive MetSyn
02
Targets
LCT (Lactase-phlorizin hydrolase)NeuraminidaseGPX4 (Glutathione peroxidase 4)IL-4 (Interleukin 4)PNLIP (Pancreatic triacylglycerol lipase)Misfolded SOD1TNFA (Tumor necrosis factor alpha (soluble))HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)GehA (Triacylglycerol lipase GehA)
Beyond the preview
Go deeper on AM3 + SynBalance Metsyn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AM3 + SynBalance Metsyn.